الفهرس 
inflammatory bowel disease (IBD)Only 14 pages are availabe for public view
 |  | from | 195 |  |  |
| | | from | 195 | | |
Abstract
The World Health Organization (WHO) ranks colorectal carcinoma (CRC) as the 3rd leading causality of death from cancer worldwide, also ranking it as the 4th most prevalent cancer type detected. The pathogenesis of CRC remains increasingly complex and interwoven. Serious symptoms related to the rectum, such as bleeding, diarrhea, abscesses, abdominal pain, fistulas, and constipation, can result from colorectal carcinoma (CRC), which begins by attacking the lining mucosa of the colon. This will lead to change in people’s dietary habits. It is important to consider four main strategies when developing colon drug delivery systems (CDDS) for the colon: (1) pH-dependent CDDS (nano systems made of polymers, formulations based on lipids, and tablets or capsules with a film coating); (2) Enzyme-sensitive CDDS (systems made of polysaccharides); (3) CDDS mediated by ligands or receptors (antibodies, peptides); and (4) Magnetically driven CDDS. However, there are good and bad points to every strategy. In CDDS, nanoparticle drug-delivery methods are seen as a possible effective treatment for colon diseases.